Monitoring Agency report for the quarter ended on June 30, 2026
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Granules India filed its quarterly Monitoring Agency Report from India Ratings & Research for the Preferential Issue of ₹1,762.50 Crores conducted in Feb 2026. The issue consisted of 51.28 lakh equity shares and 2.5 crore convertible warrants priced at ₹585 each. As of June 30, 2026, the company had received ₹665.63 Crores (₹300 Cr from full equity subscription + ₹365.63 Cr as 25% upfront on warrants). The entire equity proceeds (₹300 Cr) have been fully utilized, including ₹225 Cr invested in subsidiary Granules Life Sciences for term loan prepayment and ₹75 Cr for general corporate purposes. Of the warrant proceeds, ₹332.79 Cr has been deployed across capex (₹13.60 Cr), operations (₹16.25 Cr), subsidiary term loan prepayment (₹87.79 Cr), working capital (₹54.38 Cr), and vendor payments (₹160.77 Cr). Unutilized balance of ₹32.83 Cr sits with the subsidiary. No deviation from stated objects was observed.
This is a routine SEBI-mandated compliance filing confirming that Granules India is deploying the preferential issue funds in line with disclosed purposes, with no red flags. Shareholders can take comfort that proceeds are flowing toward stated goals like capex, working capital, and subsidiary debt prepayment, though most warrant proceeds (₹1,096.87 Cr of the remaining 75%) depend on future warrant conversion.